Pipeline
Kronos Bio is evaluating strategic alternatives per the November 13, 2024 press release
TRN
Candidate & Indication
Discovery
IND-enabling
Phase 1
Phase 2
Phase 3
MYC
Istisociclib (KB-0742)
(CDK9 inhibitor)
Platinum-resistant high-grade serous ovarian cancer
IRF4
KB-9558
(p300 KAT inhibitor)
R/R multiple myeloma
HPV-driven tumors
KB-7898
(p300 KAT inhibitor)
Sjögren’s disease
MYC
Undisclosed
β-Catenin
Undisclosed
Multiple
Undisclosed
Additional proprietary programs from mapping and screening the MYC, AR, MYB, IRF4 and other TRNs
TRN: transcription regulatory network. MYC: myelocytomatosis oncogene. CDK9: cyclin-dependent kinase 9. IRF4: interferon regulatory factor 4. KAT: lysine acetyltransferase. R/R: Relapsed/ Refractory. HPV: human papillomavirus.
We may not be successful in identifying product candidates that can selectively modulate the specific oncogenic TRNs associated with such programs.